BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2021 9:32:33 AM | Browse: 338 | Download: 556
 |
Received |
|
2021-03-23 08:25 |
|
Peer-Review Started |
|
2021-03-23 08:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-27 06:16 |
|
Revised |
|
2021-08-09 19:40 |
|
Second Decision |
|
2021-10-18 06:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-10-18 09:25 |
|
Articles in Press |
|
2021-10-18 09:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-17 06:01 |
|
Publish the Manuscript Online |
|
2021-11-19 09:32 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jenny Isaksson, Henrik Green, Dimitrios Papantoniou, Linn Pettersson, Mats Anden, Johan Rosell, Elisabeth Åvall-Lundqvist and Nils Oskar Elander |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nils Oskar Elander, MD, PhD, Doctor, Department of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping University Hospital, Linköping 58185, Sweden. nils.elander@liu.se |
| Key Words |
Prostate cancer; Chemotherapy; Docetaxel; Castration sensitive; Metastatic; Real world |
| Core Tip |
Two recent trials reported impressive outcomes when upfront docetaxel is added to androgen deprivation therapy in metastatic castration-sensitive prostate cancer (mCSPC). This study presents the outcome and safety of this treatment strategy in a real-world context of all eligible patients in the southeast region of Sweden. While the treatment is toxic in terms of febrile neutropenia and unplanned hospitalizations, the outcome and long-term prognosis appear similar in real life and randomized controlled trial contexts. Further implementation of upfront docetaxel in mCSPC in routine care is encouraged. |
| Publish Date |
2021-11-19 09:32 |
| Citation |
Isaksson J, Green H, Papantoniou D, Pettersson L, Anden M, Rosell J, Åvall-Lundqvist E, Elander NO. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World J Clin Oncol 2021; 12(11): 1009-1022 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i11/1009.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i11.1009 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
